Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis

Journal of Rheumatology

Volumn 41, Issue 11, 2014, Pages 2167-2178

  Den Boer, Ethan ^a   De Rotte, Maurits C J F ^a   Pluijm, Saskia M F ^a   Heil, Sandra G ^a   Hazes, Johanna M ^a   De Jonge, Robert ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Arthritis; Erythrocytes rheumatoid; Methotrexate; Prospective studies; Single nucleotide polymorphism

Indexed keywords

CORTICOSTEROID; FOLIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GLUCOCORTICOID; HYDROXYCHLOROQUINE; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; SALAZOSULFAPYRIDINE; POLYGLUTAMIC ACID;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ERYTHROCYTE LEVEL; ERYTHROCYTE LEVEL; FEMALE; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTICENTER STUDY (TOPIC); NETHERLANDS; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; VALIDATION PROCESS; WILD TYPE; AGE; AGED; ANALOGS AND DERIVATIVES; ARTHRITIS, RHEUMATOID; BLOOD; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECTS; ERYTHROCYTE; FOLLOW UP; MIDDLE AGED; MULTIVARIATE ANALYSIS; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; REPRODUCIBILITY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROCYTES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; POLYGLUTAMIC ACID; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923260875     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131290     Document Type: Article

References (47)

1. Strand V, Cohen S, Schiff M., Weaver A, Fleischmann R, Cannon G., et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542-50.
2. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 200; 56:1765-75.
3. Bannwarth B, Pehourcq F, Schaeverbeke T., Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30:194-210.
4. Chabner BA, Allegra CJ, Curt G.A., Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985; 76:907-12.
5. Dervieux T, Furst D, Lein D.O., Capps R., Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64:1180-5.
6. Dervieux T, Furst D, Lein D.O., Capps R., Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50:2766-74.
7. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006; 54:3095-103.
8. Dervieux T, Kremer J, Lein D.O., Capps R., Barham R, Meyer G, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate poly glutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14:733-9.
9. Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999; 17:313-20.
10. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986; 29:822-31.
11. Hroch M, Tukova J, Dolezalova P., Chladek J. An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis. Biopharm Drug Dispos 2009; 30:138-48.
12. Becker ML, van Haandel L, Gaedigk R, Lasky A., Hoeltzel M, Stobaugh J, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum 2010; 62:1803-12.
13. Becker ML, Gaedigk R, van Haandel L, Thomas B, Lasky A., Hoeltzel M, et al. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Arthritis Rheum 2011; 63:276-85.
14. den Boer E, Meesters RJ, Van Zelst BD, Luider TM, Hazes JM, Heil S G, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem 2013; 405:1673-81.
15. Dervieux T, Orentas Lein D, Marcelletti J, Pischel K., Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem 2003; 49:1632-41.
16. van Haandel L, Becker ML, Leeder J.S., Williams TD, Stobaugh JF. A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. Rapid Commun Mass Spectrom 2009; 23:3693-702.
17. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58:3299-308.
18. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C., James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009; 60:2248-56.
19. Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 2010; 49:2337-45.
20. Claessen SJ, Hazes JM, Huisman M.A., van Zeben D, Luime JJ, Weel AE. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial. BMC Musculoskelet Disord 2009; 10:71.
21. Nederlandse Vereniging voor Reumatologie. Dutch Rheumatology Society. [Medicijnen methotrexate richtlijn 2009-update 2011]. [Article in Dutch; Internet. Accessed July 23, 2014.] Available from: www.nvr.nl/uploads/ki/tO/kitOmw9WmZQBHEq61H4YMQ/NVR-Medicijnen-MTX-richtlijn-2009-update-2011.pdf
22. Weigand M, Frei E, Graf N., Wiessler M. Comparative analysis of methotrexate polyglutamates in lymphoblast preparations from bone marrow and blood, and the contribution of residual red blood cells. J Cancer Res Clin Oncol 2000; 126:407-11.
23. International HapMap Project. [Internet. Accessed July 23, 2014.] Available from: http://hapmap.ncbi.nlm.nih.gov
24. National Center for Biotechnology Information. dbSNP short genetic variations. [Internet. Accessed July 23, 2014.] Available from: http://www.ncbi.nlm.nih.gov
25. Ranganathan P, Culverhouse R, Marsh S., Mody A, Scott-Horton TJ, Brasington R, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol 2008; 35:572-9.
26. Ranganathan P. An update on methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics 2008; 9:439-51.
27. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009; 10:547-66.
28. Gradhand U, Tegude H, Burk O., Eichelbaum M, Fromm MF, Konig J. Functional analysis of the polymorphism-211C>T in the regulatory region of the human ABCC3 gene. Life Sci 2007; 80:1490-4.
29. Ostergaard M, Ernst A, Labouriau R., Dagiliene E, Kramp HB, Christensen M, et al. Cyclooxygenase-2, multidrug resistance 1, and breast cancer resistance protein gene polymorphisms and inflammatory bowel disease in the Danish population. Scand J Gastroenterol 2009; 44:65-73.
30. Boyles AL, Wilcox AJ, Taylor J.A., Shi M., Weinberg CR, Meyer K, et al. Oral facial clefts and gene polymorphisms in metabolism of folate/one-carbon and vitamin A: a pathway-wide association study. Genet Epidemiol 2009; 33:247-55.
31. De Vos L, Chanson A, Liu Z., Ciappio ED, Parnell LD, Mason JB, et al. Associations between single nucleotide polymorphisms in folate uptake and metabolizing genes with blood folate, homocysteine, and DNA uracil concentrations. Am J Clin Nutr 2008; 88:1149-58.
32. de Jonge R, Tissing WJ, Hooijberg J.H., Jansen G., Kaspers GJ, Lindemans J, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009; 113:2284-9.
33. Ansari M, Sauty G, Labuda M., Gagne V, Laverdiere C, Moghrabi A., et al. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009; 114:1383-6.
34. de Rotte MC, Bulatovic M, Heijstek M.W., Jansen G., Heil SG, van Schaik RH, et al. ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis. J Rheumatol 2012; 39:2032-40.
35. Bulatovic M, Heij stek MW, Van Dijkhuizen EH, Wulffraat NM, Pluijm SM, de Jonge R. Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis. Ann Rheum Dis 2012; 71:1484-9.
36. Hornung N, Ellingsen T, Attermann J., Stengaard-Pedersen K, Poulsen JH. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol 2008; 35:1709-15.
37. den Boer E, Meesters RJ, van Zelst BD, Luider TM, Hazes JM, Heil SG, et al. Measuring methotrexate polyglutamates in red blood cells: a new LC-MS/MS-based method. Anal Bioanal Chem 2013; 405:1673-81.
38. van Haandel L, Becker ML, Williams T.D., Leeder JS, Stobaugh JF. Measurement of methotrexate polyglutamates in human erythrocytes by ion-pair UPLC-MS/MS. Bioanalysis 2011; 3:2783-96.
39. Bulatovic Calasan M, den Boer E, de Rotte MC, Vastert SJ, Kamphuis S, de Jonge R, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients. Ann Rheum Dis 2013 (E-pub ahead of print).
40. de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Bulatovic Calasan M, Weel AE, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 2013 (E-pub ahead of print).
41. Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J., Frampton C, et al. Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2540-7.
42. Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G., Tugwell P. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000:CD000951.
43. Khanna D, Park GS, Paulus H.E., Simpson KM, Elashoff D, Cohen SB, et al. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies. Arthritis Rheum 2005; 52:3030-8.
44. de Rotte MC, de Jong PH, Pluijm SM, Calasan MB, Barendregt PJ, van Zeben D, et al. Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate. Arthritis Rheum 2013; 65:2803-13.
45. Owen SA, Hider SL, Martin P, Bruce I.N., Barton A., Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 2013; 13:227-34.
46. French D, Yang W, Cheng C., Raimondi SC, Mullighan CG, Downing JR, et al. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 2009; 113:4512-20.
47. Stark M, Wichman C, Avivi I., Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113:4362-9.